Marker Therapeutics (FRA:GX1) Cash-to-Debt : No Debt ⁽¹⁾ (As of Sep. 2024)

View and export this data going back to . Start your Free Trial

What is Marker Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Marker Therapeutics's cash to debt ratio for the quarter that ended in Sep. 2024 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Marker Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Marker Therapeutics's Cash-to-Debt or its related term are showing as below:

FRA:GX1' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.86 Med: 103.69 Max: No Debt
Current: No Debt

During the past 13 years, Marker Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 0.86. And the median was 103.69.

FRA:GX1's Cash-to-Debt is ranked better than
99.87% of 1487 companies
in the Biotechnology industry
Industry Median: 7.46 vs FRA:GX1: No Debt

Marker Therapeutics Cash-to-Debt Historical Data

The historical data trend for Marker Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Marker Therapeutics Cash-to-Debt Chart

Marker Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

90.63

1.74

3.57

1.55

No Debt

Marker Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Marker Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Marker Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Marker Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marker Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Marker Therapeutics's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Marker Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Marker Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Marker Therapeutics had no debt ⁽¹⁾.

Marker Therapeutics's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:

Marker Therapeutics had no debt ⁽¹⁾.

Marker Therapeutics (FRA:GX1) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Marker Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Marker Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Marker Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marker Therapeutics Inc (FRA:GX1) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

MRKR:USA

Address

9350 Kirby Drive, Suite 300, Houston, TX, USA, 77054

Website

http//www.markertherapeutics.com

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

Marker Therapeutics Headlines

No Headlines

Marker Therapeutics (FRA:GX1) Cash-to-Debt : No Debt (1) (As of Sep. 2024)